Recognizing that the use of biomarkers has led to advances in the detection of Alzheimer's disease (AD), researchers reviewed a PET amyloid imaging agent, finding that imaging with PiB provides early detection of disease and allows clinicians to distinguish AD from other dementias. Using this and other agents provides a valuable pathway for investigating the relationship between amyloid pathology and changes in cognition, brain structure, and function.